mdx 1342
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00639834)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19BINDING AGENT
B-lymphocyte antigen CD19 binding agent
- B-lymphocyte antigen CD19CROSS-LINKING AGENT
CD19 cross-linking agent
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109337 ↗
Also known as
- mdx 1342
- mdx-1342
- mdx-1342
- mdx-1342
- mdx-1342 antibody
- mdx1342 antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00593944 | Phase 1 | Aug 1, 2008 | Bristol-Myers Squibb |
| NCT00639834 | Phase 1 | Feb 1, 2008 | Bristol-Myers Squibb |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2008 |
1 organizations
Page 1 / 1